Skip to main contentSkip to navigationSkip to search

Delivering better treatments

Camurus is committed to improving the lives of patients
with severe and chronic diseases

Read more

updates

Latest news

Disease areas

Focus on severe and chronic diseases

Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care

Learn more on disease areas

Events

Upcoming events


See all events

  • 16 Jul

    Interim Report January-June 2024

    The interim report January-June is published on 16 July 2024.

    Add to calendar

  • 21 Aug

    SEB Nordic Large Cap Seminar

    Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in Stockholm, 21 August, at 12.50 CEST. The presentation can be seen by the conference participants. 

    Add to calendar

  • 22 Aug

    Nordea Small & Mid Cap Days

    Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in Stockholm, 22 August. The presentation can be seen by the conference participants. More information will follow closer to the event.

    Add to calendar

Products

Addressing important unmet medical needs

Learn about our products

Stories

Living with opioid dependence

Read Daniel's story

Annual General Meeting

Camurus’ Annual General Meeting 2024 was held on Wednesday, 8 May 2024 at Elite Hotel Ideon in Lund, Sweden.

See documents for Annual General Meeting 2024
See resolutions at the Annual General Meeting 2024
See more information on Camurus' general meetings

Pipeline

Diversified pipeline with large potential

Camurus' innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

See pipeline

sustainability

Sustainable solutions for a healthier world

Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.

Learn more